13F Pro quality score
Rank #2,826 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Serina Therapeutics, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $130.0K | $-19.2M | — |
| FY 2024 | 10-K | $56.0K | $-11.1M | — |
| FY 2023 | 10-K | $3.2M | $5.3M | -99.2% |
| FY 2022 | 10-K | $34.0K | $-10.5M | — |
| FY 2021 | 10-K | $144.0K | $-8.7M | — |
| FY 2020 | 10-K | $361.0K | $-10.9M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Serina Therapeutics, Inc. (SER) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SER at 14.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,826 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Serina Therapeutics, Inc. reports net income of $-6.4M, free cash flow of $-6.7M. Top institutional holders of SER by reported 13-F value include Sio Capital Management, VANGUARD CAPITAL MANAGEMENT, Waverly Advisors, based on the most recent SEC filings. SER trades on the NYSE exchange and files with the SEC under CIK 1708599. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SER daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Serina Therapeutics, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1708599 →